CytoSorbents Announces 2020 Financial and Operational Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/20/2026
- Wall St slips on rising bond yields; Walmart results weigh
- Walmart shares fall despite earnings beat
- Alibaba stock dips as Q2 profit misses estimates despite strong AI cloud growth
- Wolfe remains "broadly bullish on AI semis stocks", names Top Pick
- Moderna stock pulls back after massive one-day rally: analysts weigh in
- Marvell issues Google warrant tied to custom chip deal
- FOMC minutes from July 28-29th meeting
- US stock futures steady after tech slump; investors focus on Middle East tensions
- Lowe's Cos. (LOW) Tops Q2 EPS by 17c, Misses on Revenue; Offers Fy27 Guidance
- Deutsche Bank calls Treasury buyback doubling similar to ’operation twist’
Cytosorbents (CTSO) Reports Q4 Revenues Beat
March 9, 2021 4:21 PM ESTCytosorbents (NASDAQ: CTSO) reported Q4 revenue for the quarter came in at $12 million versus the consensus estimate of $10.95 million.
Q4 2020 Results
Q4 2020 total revenue was approximately $12.0 million versus $7.4 million a year agoProduct sales growth accelerated in Q4 2020, with record quarterly product sales of approximately $11.5 million, a 74% increase from $6.6 million in Q4 2019Product gross margins were a record high of 82% in Q4 2020 versus 80% in Q4 2019Dr. Phillip Chan, MD, PhD, Chief Executive Officer of CytoSorbents stated, "In our recent stockholder letter, I discussed how the company successfully navigated a... More
